Jose Aparicio

University of Southern California Keck School of Medicine
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (9)

Monoclonal gammopathy of undetermined significance (MGUS) is a necessary precursor of multiple myeloma (MM). Compared to non-Hispanic Whites (Whites), African Americans experience about 2-fold greater, and Asian Americans 50% lower, occurrence of MGUS and MM. We examined determinants of MGUS and progression to MM or other plasma cell neoplasms (PCN) among Japanese American, African American, Latino, Native Hawaiian, and White participants in a case-control study nested in the Multiethnic Cohort (MEC) Study. Presumptive cases included MEC participants 65+ years old initially screened using the Medicare billing code for paraproteinemia along with those with MM/PCN at least one year after blood draw. Presumptive controls had no Medicare billing code or MM. Laboratory confirmation resulted in 426 confirmed MGUS cases (370 non-IgM and 56 IgM) and 863 MGUS-free controls. We used multivariable logistic regression and Cox regression to estimate associations with MGUS and MGUS progression. The distribution of immunoglobulin (Ig) isotypes differed by race/ethnicity (P=0.005): Japanese Americans had the lowest (11.0%) and Native Hawaiians the highest (23.5%) proportion of IgA. Each unit increase in BMI (kg/m2) was associated with a 6% increase in non-IgM MGUS (95% CI= 3-9%) among all racial/ethnic groups combined. BMI was also significantly associated within most racial/ethnic groups, especially among Native Hawaiians (13% increase per BMI unit), and with IgA and IgG MGUS. Progression to MM or other PCN was associated with an M-spike >1.5 g/dL, but not with BMI. BMI was the main determinant associated with MGUS, but not with progression. Isotype distribution differed between racial/ethnic groups.

Year:

2026

Background: Multiple myeloma (MM) is the most common hematologic neoplasm among African Americans (AA), who have a 1.5-2-fold excess compared to Whites. Older age, male sex and obesity are also established risk factors. There is a knowledge gap regarding the tumor microenvironment (TME) in MM, especially in AA's. It is important to understand the effect of the host risk factors on the tumor microenvironment and the arrangement of immune architecture in this high-risk population group. Methods: We assessed the tumor microenvironment (TME) of 30 diagnostic MM bone marrow samples (61 regions of interest, 516,328 cells) from AA patients who previously participated in a genome-wide association scan, using imaging mass cytometry (IMC) to identify differences linked to patient characteristics (sex, age, and obesity). Obesity was defined using the WHO categories which classified BMI into normal weight, overweight obese and severely obese. Hypercellular regions were identified on diagnostic slides reviewed by a hematopathologist. Cores of 0.5 mm in diameter and 4 microns in thickness were taken for analysis. Antibody-metal conjugation was conducted with Maxpar labeling kit (Standard Biotools). Antigen retrieval was performed with tris-EDTA solution. The slides were incubated with metal-tagged antibodies overnight, washed, and dried before ablation. Statistical methods: The ablated imaging data was processed into single cell objects using supervised training of multiple major cellular phenotypes including macrophages (CD68, CD163, iNOS), lymphocytes (CD3, CD4, CD8, CD20, CD45RO, FOXP3,) fibroblasts (vimentin), endothelial cells (aSMA, EprhinB2, CD31), fat (adiponectin), myeloma cells (CD138, MUM1) and bone (collagen) from the panel. The data were clustered into the major TME phenotypes identified using self-organized mapping (SOM) which were labeled using lineage markers to identify the major TME compartments. The abundance was modeled using negative-binomial regression with the cellular total as the offset; nearest neighbor distances (NND) were crossed by all pairs and compared using logistic regression. Clusters were annotated using linear mixed effects model of standardized (Z-scale) expression. Associations were estimated using multivariable linear regression in R. Results: The TME comprised hematopoietic cells (56%) endothelial/fibroblasts (27%), myeloma cells (12%), fat (4.3)%, and collagen representing bone (0.19%). Among hematopoietic cells there were CD45+ (βCD45=0.66 (0.56, 0.71); p<0.01) hematopoietic cells not otherwise specified (44%), cytotoxic T-cells (CTLs) (22%), macrophages (22%) B-cells (9%),FoxP3 (2%) and CD4+ cells (<1%). There were 13 (46%) males. The average age was 59 years (sd=11.8 years). Our set consisted of 7 (26%) normal weight, 11 (41%) overweight, 6 (22%) obese and 3 (11%) morbidly obese patients. Increasing age was positively associated with an increasing abundance of B-cells (p<0.001) and bone (p=0.02) and inversely associated with the abundance of endothelial cells (ECs) (p<0.01) and fibroblasts (p<0.01). Females had significantly higher abundance of bone (p<0.001) and ECs (p<0.001), but we did not detect differences in other TME phenotypes by sex. Compared to normal BMI, there were no significant associations between CTLs and overweight, or obese patients' tumors. However, a significant increase in the abundance of CTLs was observed in tumors from patients who were severely obese compared to those with normal BMI (β= 1.88 (1.22, 2.9), p<0.01). Increasing abundance of ECs was associated with increasing BMI categories (β=6.6 (1.8,22.5), p<0.001). Spatial summary We did not detect differences in NND of any major phenotypes by age or sex. In tumors from morbidly obese individuals compared to normal BMI individuals, CTLs were significantly closer to myeloma cells (p<0.01), fibroblasts (p=0.02) and B-cells (p=0.01). There were no differences in spatial distances observed for oth

Year:

2024

Classic Hodgkin Lymphoma (CHL) is a B-cell lymphoma characterized by Hodgkin Reed- Sternberg (HRS) cells surrounded by immune cell infiltrates that define histological subtypes. A subset of CHL tumors shows integration of the Epstein-Barr virus (EBV) genome into the HRS cell. EBV tumor positivity is thought to reflect immunocompromised status and has been more common in young and older patients, and non-white patients of lower socioeconomic status. This study aims to examine the distribution of EBV tumor prevalence and determine whether EBV tumor status affects survival, focusing on potential disparities across age, sex, or race/ethnicity. We collected 908 multiethnic cases of formalin-fixed paraffin-embedded tumor blocks of CHL for the MultiEthnic Study of Hodgkin lymphoma (MESH) from multiple sites, including cancer centers, hospitals, and Residual Tissue Repositories. Diagnosis confirmation was conducted by a hematopathologist. Demographic and clinical information were obtained from medical charts and state cancer registries. EBV tumor status was determined using EBER1 in situ hybridization, with EBV+ cases defined by nuclear or cytoplasmic positivity in >5% of HRS cells. We tested associations between EBV tumor status and age at diagnosis (pediatric: <15 years, adolescent/young adult [AYA]: 15-39 years, older adults: 40+ years), sex, race/ethnicity (Hispanic, Black, Non-Hispanic White[NHW], Asian, and Hawaiian/Pacific Islander [HPI]), and histology (Nodular Sclerosis[NS]; Mixed Cellularity[MC]) using χ-squared tests. We tested the effect of EBV on 5-year overall survival (OS), using Kaplan-Meier and multivariable Cox regression analysis adjusted for age at diagnosis, sex, and race/ethnicity. Of the 685 cases diagnosed from 1978 to 2018 with EBV results, about 30% were EBV+. EBV positivity for both NS and MC was higher in pediatric cases (NS: 45%; MC: 90%) and older-aged cases (NS: 29%; MC: 64%) compared to AYA cases (NS: 16%; MC: 39%). AYA had the most CHL cases, mostly EBV−. Males made up more EBV+ cases, with pronounced differences across all age groups (pediatric: 62%; AYA: 24%; older-aged: 46%). EBV positivity varied by race/ethnicity (p=0.002), with the highest prevalence in Hispanics (38%) and the lowest in HPI (10%). EBV+ tumors rose with age in NHW and HPI racial groups, but other racial/ethnic groups showed a decline in prevalence among AYA patients. Adjusted Cox analyses showed no statistically significant association between EBV tumor status and OS (HR=1.08, p=0.744). Stratified analysis showed divergent effects of EBV on OS in AYA and older adult age groups, although the associations were not significant (HR=0.79, p=0.671; HR=1.11, p=0.6842, respectively). Race-specific trends were observed in EBV+ CHL across age groups. Unlike previous reports, we did not observe an association between EBV tumor status and survival. More studies with diverse populations and larger sample sizes are needed to fully grasp the complex interplay between demographic and clinical factors and EBV patterns in CHL tumors across different populations. Citation Format: Esther Lam, Jia Y. Wan, Jose Aparicio, Sheeja Pullarkat, Anthony Colombo, Joo Song, Chun Chao, Juan M. Mejia-Arangure, Brenda Hernandez, Aixiang Jiang, Tomohiro Aoki, Pamela Allen, Christopher Flowers, Sophia Wang, Juanita Evans, Owen Chan, Leon Bernal-Mizrachi, David W. Scott, Megan Lim, Jakub Svoboda, Christian Steidl, Imran Siddiqi, Wendy Cozen. EBV prevalence and overall survival in the MultiEthnic Study of Hodgkin lymphoma (MESH) [abstract]. In: Proceedings of the 17th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2024 Sep 21-24; Los Angeles, CA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2024;33(9 Suppl):Abstract nr A026.

Year:

2024

This abstract is being presented as a short talk in the scientific program. A full abstract is printed in the Proffered Abstracts section (PR008) of the Conference Program/Proceedings. Citation Format: Lenora WM Loo, Yuquing Li, Kami K. White, Jose A. Aparicio, Veronica W. Setiawan, Christopher A. Haiman, Anna H. Wu, Lynne R. Wilkens, Loic Le Marchand, Brenda Y Hernandez, Iona Cheng. Racial and Ethnic Differences in the Biological Signatures of Breast Tumors and the Immune-microenvironment: The Multiethnic Cohort Study [abstract]. In: Proceedings of the 17th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2024 Sep 21-24; Los Angeles, CA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2024;33(9 Suppl):Abstract nr C146.

Year:

2024

Lung cancer remains the leading cause of cancer-related mortality globally and continues to contribute significantly to cancer health disparities. Black/African American (B/AA) men exhibit a higher risk of lung cancer compared to White men; B/AA individuals also exhibit lower 5-year survival and stage-specific survival rates than White subjects. Biological factors, including genetic differences in cancer driver mutation, may influence this disparity. Lung adenocarcinoma (LUAD) is the most common histological subtype of lung cancer across all ethnic groups, including B/AA individuals. Our study aims to characterize the main driver and co-mutation signatures of LUAD in B/AA individuals, who are significantly underrepresented in current mutational studies. We hypothesize that B/AA individuals will have a unique repertoire of cancer driver genes, which could contribute to genetic differences and response to targeted therapies compared to LUAD of White subjects. We are obtaining 100 de-identified archival formalin-fixed, paraffin-embedded (FFPE) LUAD samples from B/AA subjects from cancer registries in Florida and California. Extraction of DNA from the FFPE samples is in progress, and samples have been sent for whole exome sequencing (WES) and ancestry determination. This data will then be analyzed and compared with known LUAD mutation profiles from other ethnicities. Identification of cancer driver mutations will then inform the development of in vitro models for therapeutic testing. To date, the limited information on cancer driver genes in LUAD from B/AA subjects suggests that KRAS is the most common cancer driver gene, just like in LUAD from White subjects, and is found in ∼34% of cases. Therefore, we anticipate identifying KRAS mutations similar to this proportion based on the collection of previously published literature analyses. One key goal of this study is to obtain more information about the exact spectrum of KRAS mutations in LUAD from B/AA subjects. In addition, our work may unveil new variants of known cancer driver mutations such as KRAS, EGFR, BRAF, etc., and finally, “new” driver genes. Our efforts will address critical gaps in the understanding of lung cancer driver genes, a key step to developing personalized treatment of lung cancer and mitigating cancer health disparities between B/AA and White individuals. Supported by grants U54CA233396, U54CA233444, and U54CA233465 from the National Institutes of Health (NIH)/National Cancer Institute (NCI), the Norris Comprehensive Cancer Center core grant, award number P30CA014089 from the NIH/NCI, and by the Undergraduate Research Associates Program supported by the USC Provost. Citation Format: Davin Pan, Daniel J. Mullen, Colton Stensrud, Jose Aparicio, Christina M. Gobin, Sofia Lugo, Kweku Ofosu-Asante, Justin K. Mensah-Mamfo, Kyle R Phillips, Yong Huang, Nazarius S. Lamango, William D Wallace, Suhn K Rhie, Kristinanna M. Fredenburg, Ite A. Offringa. Identifying cancer driver mutation signatures in lung adenocarcinoma from Black/African American individuals: Addressing cancer health disparities [abstract]. In: Proceedings of the 17th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2024 Sep 21-24; Los Angeles, CA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2024;33(9 Suppl):Abstract nr C171.

Year:

2024

Background: In the U.S., there are stark racial and ethnic differences in the incidence and mortality of breast cancer that cannot be fully explained by lifestyle and environmental factors. The contribution of tumor biology to these differences in breast cancer outcomes across race and ethnicity is poorly understood. We conducted a preliminary analysis of the racial and ethnic differences in the gene expression profiles of biological signatures of breast tumors within in the Multiethnic Cohort Study (MEC). Methods: For 279 postmenopausal females with invasive breast cancer within the MEC, we examined 42 breast cancer signatures based on gene expression profiling of formalin-fixed paraffin-embedded breast tumors using the NanoString nCounter Breast Cancer 360™ (BC360) Panel. This included 36 African American, 62 Japanese American, 51 Latino, 65 Native Hawaiian, and 65 White females. Multivariable linear regression was conducted to examine racial and ethnic differences in gene expression levels, adjusting for age at diagnosis, stage (localized or regional/distant), and hormone receptor status (HR- positive, negative, or unknown). A Bonferroni corrected p-value threshold of 0.0019 (p=0.05/42 tests) was used to determine statistical significance. Results: We identified racial and ethnic differences in breast tumor gene expression signatures for four broad categories of breast tumor biology: breast cancer-specific, tumor, immune, and tumor microenvironment. Specifically, the differentially expressed signatures in these four categories were: breast cancer-specific (CDK4 p<0.001; ER-signaling p=0.013), tumor (apoptosis p=0.004; p53 p=0.002; proliferation p=0.026; cell adhesion p=0.029; SOX2 p=0.002), immune (B7-H3 p=0.024; CD8 T-cells p=0.037; MHC2 p=0.032) and tumor microenvironment (hypoxia p=0.022) signatures. Racial and ethnic differences in the expression levels of the cyclin-dependent kinase 4 (CDK4) signature was found to be statistically significant (p<0.001). In comparison to White females, increased expression of the CDK4 signature was observed in breast tumors of African American (p=0.001) and Latino (p=0.001) females and no differences were observed for Japanese American and Native Hawaiian females. Conclusion: Our preliminary results suggest racial and ethnic differences in breast tumor biology and the immune-microenvironment. As CDK4 is a key regulator of cell cycle progression, the increased expression of CDK4 in breast tumors from African American and Latino females compared to White females may reflect greater proliferation activity. CDK4 is a drug target of CDK4/6 inhibitors that could potentially serve as a basis for population-guided treatment strategies. Future work will examine additional breast tumor samples and evaluate association with clinico-pathological characteristics and survival across this multiethnic population. Citation Format: Lenora WM Loo, Yuquing Li, Kami K. White, Jose A. Aparicio, Veronica W. Setiawan, Christopher A. Haiman, Anna H. Wu, Lynne R. Wilkens, Loic Le Marchand, Brenda Y. Hernandez, Iona Cheng. Racial and Ethnic Differences in the Biological Signatures of Breast Tumors and the Immune-microenvironment: The Multiethnic Cohort Study [abstract]. In: Proceedings of the 17th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2024 Sep 21-24; Los Angeles, CA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2024;33(9 Suppl):Abstract nr PR008.

Year:

2024

Year:

2023

Year:

2020

Year:

2020

Collaborators (7)

Ite Adriana Offringa

Professor

University of Southern California

UNITED STATES
View details

Nazarius Lamango

Professor

Florida A&M University College of Pharmacy and Pharmaceutical Sciences

UNITED STATES
View details

Daniel Stram

Professor

University of Southern California

UNITED STATES
View details

Leon Bernal-Mizrachi

Professor and Chair

Wake Forest Baptist Medical Center

UNITED STATES
View details

Romonia Renee Reams

Professor

Florida A&M University

UNITED STATES
View details

Edward Agyare

Professor and Director

Florida A&M University

UNITED STATES
View details

Aaron Rosenberg

University of California Davis Comprehensive Cancer Center

UNITED STATES
View details